BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel) 2020;13:E116. [PMID: 32512768 DOI: 10.3390/ph13060116] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Hadamitzky M, Schedlowski M. Harnessing associative learning paradigms to optimize drug treatment. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.03.002] [Reference Citation Analysis]
2 Papp M, Cubala WJ, Swiecicki L, Newman-Tancredi A, Willner P. Perspectives for therapy of treatment-resistant depression. Br J Pharmacol 2021. [PMID: 34128229 DOI: 10.1111/bph.15596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Denee T, Ming T, Waller J, Bailey T, Rajkovic-Hooley O, Middleton-Dalby C, Le HH, Zhang Q, McCrone P, Taylor D. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. Curr Med Res Opin 2021;37:311-9. [PMID: 33253055 DOI: 10.1080/03007995.2020.1857580] [Reference Citation Analysis]
4 Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol 2021;35:890-900. [PMID: 34238049 DOI: 10.1177/02698811211013579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Dominiak M, Antosik-Wójcińska AZ, Wojnar M, Mierzejewski P. Electroconvulsive Therapy and Age: Effectiveness, Safety and Tolerability in the Treatment of Major Depression among Patients under and over 65 Years of Age. Pharmaceuticals (Basel) 2021;14:582. [PMID: 34207157 DOI: 10.3390/ph14060582] [Reference Citation Analysis]
6 Li W, Ali T, Zheng C, Liu Z, He K, Shah FA, Ren Q, Rahman SU, Li N, Yu ZJ, Li S. Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression. J Neuroinflammation 2021;18:38. [PMID: 33526073 DOI: 10.1186/s12974-021-02091-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Zhong X, Ouyang C, Liang W, Dai C, Zhang W. (2R,6R)-Hydroxynorketamine Alleviates Electroconvulsive Shock-Induced Learning Impairment by Inhibiting Autophagy. Neuropsychiatr Dis Treat 2021;17:297-304. [PMID: 33568909 DOI: 10.2147/NDT.S278422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Plenge P, Yang D, Salomon K, Laursen L, Kalenderoglou IE, Newman AH, Gouaux E, Coleman JA, Loland CJ. The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter. Nat Commun 2021;12:5063. [PMID: 34417466 DOI: 10.1038/s41467-021-25363-3] [Reference Citation Analysis]
9 Pereira M, Siba IP, Acco A, Correia D, Lapa FR, Santos ARS, Ruani AP, Pizzolatti MG, Andreatini R. Myricitrin exhibits antidepressant-like effects and reduces IL-6 hippocampal levels in the chronic mild stress model. Behav Brain Res 2022;429:113905. [PMID: 35490774 DOI: 10.1016/j.bbr.2022.113905] [Reference Citation Analysis]
10 Ahmed ZS, Sherin RPV, Fonseca TL, Hoang TD, Shakir MKM. Improvement of depression in a patient with hypothyroidism and deiodinase polymorphism with LT3 Therapy. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5651] [Reference Citation Analysis]
11 Xu Y, Lu J, Yao B, Zhang Y, Huang S, Liu J, Zhang Y, Guo Y, Wang X. P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats. Toxicol Appl Pharmacol 2021;431:115735. [PMID: 34610281 DOI: 10.1016/j.taap.2021.115735] [Reference Citation Analysis]
12 Gabriel FC, Stein AT, de Melo DO, Henrique Fontes-Mota GC, Dos Santos IB, de Oliveira AF, Fráguas R, Ribeiro E. Quality of clinical practice guidelines for inadequat response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review. BMJ Open 2022;12:e051918. [PMID: 35365512 DOI: 10.1136/bmjopen-2021-051918] [Reference Citation Analysis]
13 McKeown L, Taylor RW, Day E, Shah R, Marwood L, Tee H, Kerr-Gaffney J, Oprea E, Geddes JR, McAllister-Williams RH, Young AH, Cleare AJ. Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment. J Psychopharmacol 2022;:2698811221089042. [PMID: 35475375 DOI: 10.1177/02698811221089042] [Reference Citation Analysis]
14 Chen F, Sidhom E, Yang S, Ruiz-Mendoza E, Essem J. Case report: delayed response after electroconvulsive therapy in a patient with major depressive disorder. BMC Psychiatry 2021;21:50. [PMID: 33478427 DOI: 10.1186/s12888-021-03053-0] [Reference Citation Analysis]
15 Lampela P, Tanskanen A, Lähteenvuo M, Tiihonen J, Taipale H. Switches and early discontinuations of antidepressant medication in young adults with depression. J Affect Disord 2021;295:1474-81. [PMID: 34565589 DOI: 10.1016/j.jad.2021.09.034] [Reference Citation Analysis]
16 Forte A, Pompili M, Imbastaro B, De Luca GP, Mastrangelo M, Montalbani B, Baldessarini RJ. Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. J Psychopharmacol 2021;35:1074-80. [PMID: 34291676 DOI: 10.1177/02698811211029738] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Duică L, Antonescu E, Totan M, Boța G, Silișteanu SC. Borderline Personality Disorder “Discouraged Type”: A Case Report. Medicina 2022;58:162. [DOI: 10.3390/medicina58020162] [Reference Citation Analysis]
18 Mössinger H, Kostev K. Age effects on treatment patterns in 138,097 patients with unipolar depression followed in general practices in Germany. J Psychiatr Res 2021;144:208-16. [PMID: 34700208 DOI: 10.1016/j.jpsychires.2021.10.033] [Reference Citation Analysis]
19 Gałecki P, Samochowiec J, Mikułowska M, Szulc A. Treatment-Resistant Depression in Poland—Epidemiology and Treatment. JCM 2022;11:480. [DOI: 10.3390/jcm11030480] [Reference Citation Analysis]
20 Soogrim V, Ruberto VL, Murrough J, Jha MK. Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. Drug Des Devel Ther 2021;15:151-7. [PMID: 33469267 DOI: 10.2147/DDDT.S240862] [Reference Citation Analysis]
21 Perugi G, Calò P, De Filippis S, Rosso G, Vita A, Adami M, Ascione G, Morrens J, Delmonte D. Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study. Front Psychiatry 2021;12:769693. [PMID: 34803777 DOI: 10.3389/fpsyt.2021.769693] [Reference Citation Analysis]
22 Zeng J, Ji Y, Luan F, Hu J, Rui Y, Liu Y, Rao Z, Liu R, Zeng N. Xiaoyaosan ethyl acetate fraction alleviates depression-like behaviors in CUMS mice by promoting hippocampal neurogenesis via modulating the IGF-1Rβ/PI3K/Akt signaling pathway. Journal of Ethnopharmacology 2022;288:115005. [DOI: 10.1016/j.jep.2022.115005] [Reference Citation Analysis]
23 Dodd S, Bauer M, Carvalho AF, Eyre H, Fava M, Kasper S, Kennedy SH, Khoo J, Lopez Jaramillo C, Malhi GS, Mcintyre RS, Mitchell PB, Castro AMP, Ratheesh A, Severus E, Suppes T, Trivedi MH, Thase ME, Yatham LN, Young AH, Berk M. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? The World Journal of Biological Psychiatry 2021;22:483-94. [DOI: 10.1080/15622975.2020.1851052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Alkahtani ME, Aodah AH, Abu Asab OA, Basit AW, Orlu M, Tawfik EA. Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder. Pharmaceutics 2021;13:891. [PMID: 34208460 DOI: 10.3390/pharmaceutics13060891] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]